This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Destiny Pharma Beheer

Beheer criteriumcontroles 3/4

Destiny Pharma's CEO is Chris Tovey, appointed in Sep 2023, has a tenure of less than a year. total yearly compensation is £123.00K, comprised of 89.4% salary and 10.6% bonuses, including company stock and options. directly owns 0.042% of the company’s shares, worth €1.40K. The average tenure of the management team and the board of directors is 3.4 years and 6.3 years respectively.

Belangrijke informatie

Chris Tovey

Algemeen directeur

UK£123.0k

Totale compensatie

Percentage CEO-salaris89.4%
Dienstverband CEOless than a year
Eigendom CEO0.04%
Management gemiddelde ambtstermijn3.4yrs
Gemiddelde ambtstermijn bestuur6.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Chris Tovey's beloning veranderd ten opzichte van Destiny Pharma's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Dec 31 2023UK£123kUK£110k

-UK£6m

Compensatie versus markt: Chris's total compensation ($USD157.25K) is below average for companies of similar size in the German market ($USD531.21K).

Compensatie versus inkomsten: Insufficient data to compare Chris's compensation with company performance.


CEO

Chris Tovey (59 yo)

less than a year

Tenure

UK£123,000

Compensatie

Mr. Christopher John Tovey, also known as Chris, BSc, serves as Chief Executive Officer & Director of Destiny Pharma plc since September 1, 2023. He had been the Chief Operating Officer at GW Pharmaceutica...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Christopher Tovey
CEO & Directorless than a yearUK£123.00k0.042%
£ 1.9k
William Love
Founder27.6yrsUK£250.00k6.8%
£ 309.2k
Shaun Claydon
CFO, Company Secretary & Director5.8yrsUK£270.00k0.025%
£ 1.2k
Debra Barker
Interim CMO & Senior Independent Directorless than a yearUK£213.00k0.092%
£ 4.2k

3.4yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren management: D89's management team is considered experienced (3.4 years average tenure).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Christopher Tovey
CEO & Directorless than a yearUK£123.00k0.042%
£ 1.9k
William Love
Founderno dataUK£250.00k6.8%
£ 309.2k
Shaun Claydon
CFO, Company Secretary & Director5.8yrsUK£270.00k0.025%
£ 1.2k
Debra Barker
Interim CMO & Senior Independent Director4.6yrsUK£213.00k0.092%
£ 4.2k
Anthony Nigel Rudd
Independent Chairman8yrsUK£34.00k3.93%
£ 178.7k
Richard Proctor
Member of Scientific Advisory Board6.3yrsgeen gegevensgeen gegevens
Nigel Brooksby
Non-Executive Director2.2yrsUK£41.00k0.36%
£ 16.6k
Vance Fowler
Member of Scientific Advisory Board6.3yrsgeen gegevensgeen gegevens
David Roblin
Chair of the Scientific Advisory Board6.3yrsUK£10.66kgeen gegevens
Leonard Mermel
Member of Scientific Advisory Board6.3yrsgeen gegevensgeen gegevens
Glenn J. Whitman
Member of Scientific Advisory Board6.3yrsgeen gegevensgeen gegevens
E Dellinger
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

6.3yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: D89's board of directors are considered experienced (6.3 years average tenure).